Information summarized from SensUs wiki

SensUs 2020

TARGET: Valproate

In 2020 we were challenged to build a biosensor able to quantify an anti-epileptic drug. The importance of monitoring one of the drugs given to people suffering from epilepsy is huge, for two main reasons: 

  1. Often there is a non-linear relation between the administered dose and the blood drug concentration
  2. There is a high inter-individual variability

The theme announcement video can be watched below:

https://www.facebook.com/SensUsCompetition/videos/389471081711355/

SensUs 2019

TARGET: Adalimumab

The theme of SensUs 2019 was “Managing rheumatic disease, by measuring with ease”. The disease focus was Rheumatoid Arthritis and the molecule to be detected was Adalimumab. Adalimumab is a biological drug that binds to TNF-alpha, a pro-inflammatory cytokine. The overexpression of this cytokine plays an important role in rheumatoid arthritis. Many patients do not respond to treatment with Adalimumab or lose response during treatment.

SensUs 2018

TARGET: Vancomycin

The theme was “Measuring antibiotics for better healthcare”. The teams developed biosensors for the detection of vancomycin, an important last resort antibiotic drug.

SensUs 2017

TARGET: NT-proBNP

NT-proBNP is an important biomarker for heart failure.

SensUs 2016

TARGET: Creatinine

Creatinine is a key biomarker for kidney failure.